# Hepalys Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hepalys-pharma

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Total disclosed funding: $11M
- Latest round: Series A (Sep 29, 2023)
- Investors on record: 1

## About

Based in Tokyo, Japan, and founded in 2021, Hepalys Pharma, Inc. operates as a developer of lanifibranor, a drug candidate for the treatment of non-alcoholic fatty liver disease. As of 2023, the company is led by CEO BT Slingsbee. In September 2023, Hepalys Pharma, Inc. raised venture funding from Mitsubishi UFJ Capital. As of 2023, Hepalys Pharma, Inc. is currently operating in stealth mode. The company has investors, including Catalys Pacific, Mitsubishi UFJ Capital, DBJ Capital, and MEDIPAL Innovation Fund. 

The company develops and commercialize Inventiva's proprietary drug candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH) in Japan and South Korea.

## Funding rounds

- Series A, Sep 29, 2023, $11M — Mitsubishi UFJ Capital

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A